Dennis M. Lanfear, President
Denny spent thirteen years at Amgen where he was a Corporate Officer and Vice-President. His tenure there began in 1986 when he founded the Process Development Department. Under his ten-year leadership this group became the preeminent organization of its type in BioPharma and a key strategic advantage for the company, as it remains today. As Vice President Process Development and Operations Systems, he directed the business process integration of Operations and Quality staff world-wide.

During his Amgen tenure, he had leadership roles in several development programs including those for wound healing, growth factors, and neurotrophins, directing efforts from post-discovery to Phase III. He managed the corporate product development relationship with SmithKlineBeecham from 1986 to 1990. He managed and had direct budgetary responsibility for the $135MM development partnership with Regeneron Pharmaceuticals from 1990 to 1999. He was also named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for Epogen^TM, a multibillion dollar drug.

Prior to Amgen, Denny was at Baxter International where he designed kilogram scale computerized protein purification systems. He is currently founder and CEO of Saronyx, Inc., a drug development software services company with major biopharmaceutical clients. Lanfear Capital invests in early-stage therapeutic product and device companies; its portfolio includes Asilomar Pharmaceuticals, Coapt Systems, EndoVx, and others. Lanfear Capital is also a Limited Partner in select venture funds. Denny earned degrees in Chemical Engineering and Biochemistry from Michigan State University and holds an MBA from the Anderson School at UCLA.